Neurogene

Neurogene is a clinical-stage gene therapy company headquartered in New York, NY, focused on developing transformative treatments for severe neurological diseases with limited or no existing therapeutic options. The company's lead program, NGN-101, is an adeno-associated virus (AAV)-based gene therapy candidate designed to address CLN5 Batten disease, a rare and fatal pediatric neurodegenerative disorder. Central to Neurogene's approach is its proprietary EXACT (EXpression Attenuation via Constructed Transgene) technology platform, which enables precise regulation of transgene expression within the central nervous system. This capability is designed to reduce the risk of toxicity associated with transgene overexpression, a critical challenge that has historically limited gene therapy development in neurological indications.

Neurogene operates as a publicly traded company, reflecting investor confidence in its differentiated platform and pipeline strategy. NGN-101 has advanced into clinical evaluation, positioning Neurogene among a select group of companies pursuing direct CNS gene therapy for ultrarare pediatric diseases. The company's progress with CLN5 Batten disease is particularly notable given the condition's rapid progression and the absence of approved disease-modifying therapies, underscoring the unmet medical need driving its development efforts. Neurogene's public status also provides it with access to capital markets to support ongoing clinical trials and pipeline expansion.

Neurogene represents an important presence in the broader neurotechnology and neuropharmaceuticals landscape by demonstrating how precision gene therapy can be engineered to address the unique biological challenges of the CNS. Its EXACT platform has potential applications beyond CLN5 Batten disease, suggesting a scalable foundation for tackling multiple neurogenetic disorders. At a time when gene therapy is rapidly maturing as a therapeutic modality, Neurogene's focus on expression control addresses one of the field's most pressing safety concerns and could influence how next-generation CNS gene therapies are designed industry-wide. The company exemplifies the convergence of molecular engineering and neuroscience that is defining the frontier of modern neurotherapeutics.